Rozanc J

ORCID: 0000-0003-4283-6087 · 1 paper in corpus · active 2019
2019
DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties.
Translational oncology ·doi:10.1016/j.tranon.2019.04.005

Development of novel bioactive compounds against KRAS and/or BRAF mutant colorectal cancer (CRC) is currently an urgent need in oncology. In addition, single or multitarget kinase inhibitors against MEK/ERK and PI3K/AKT pathways are of pote…